The effect of hormonal treatment on conspicuity of prostate cancer: implications for focal boosting radiotherapy

Radiother Oncol. 2012 May;103(2):233-8. doi: 10.1016/j.radonc.2011.12.007. Epub 2012 Jan 20.

Abstract

Background and purpose: For focal boosting of prostate tumors, three questions are important regarding the use of hormonal therapy. Does prolonged hormonal treatment affect the conspicuity of tumor tissue on diffusion weighted imaging (DWI) and dynamic contrast-enhanced (DCE-MRI) images? Is tumor delineation possible in patients using hormonal treatment? Can we identify specific imaging thresholds for tumor delineation in patients after prolonged androgen deprivation?

Materials and methods: Ninety-six patients were included. Using multivariate linear regression analyses, we investigated if DWI and DCE-MRI parameter maps are different in patients receiving hormonal treatment for 0-3 or >3 months. Furthermore, logistic regression was performed to obtain specific imaging thresholds for tumor tissue for the two patient groups.

Results: We found a significantly higher diffusion and lower perfusion of tumor tissue in the >3 months hormonal treatment group compared to the 0-3 group. This resulted in lower tumor conspicuity. Nevertheless, in 18/21 of the patients in the >3 months treatment group, a suspicious lesion could be defined based on the MR images. Based on logistic regression, different imaging thresholds should be set for tumor detection in the two treatment groups.

Conclusions: Prolonged androgen deprivation decreases tumor conspicuity. Different imaging thresholds need to be set to delineate tumor in patients who have had prolonged hormonal treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / therapeutic use*
  • Brachytherapy
  • Diffusion Magnetic Resonance Imaging
  • Humans
  • Iodine Radioisotopes / therapeutic use
  • Logistic Models
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy*
  • Radiotherapy, Intensity-Modulated
  • Retrospective Studies

Substances

  • Androgen Antagonists
  • Iodine Radioisotopes